Highlighted News
ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing
Sep 17, 2024
ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing
Research Paper About Novel RNA Restriction Enzyme Published in Journal: Nucleic Acids Research
Sep 16, 2024
ArcticZymes Technologies ASA Publishes Innovative Research on Novel RNA Restriction Enzyme, Paving the Way for Precision RNA Manipulation
ArcticZymes Technologies Q2 and 6M 2024 Results – Progress in partnership discussions and portfolio development
Aug 22, 2024
Tromsø, Norway, Aug 22, 2024 – ArcticZymes Technologies (OSE: AZT) reported revenues of NOK 27.5 million and an EBITDA of NOK 2.6 million for the second quarter of 2024.
Announcement of New Chairman and Board Members
Jun 27, 2024
Tromsø, Norway, June 27th, 2024—ArcticZymes Technologies (OSE: AZT) Announces Announces New Chairman and Board Members
Nomination of Dr. Frank Mathias as Chairman of the Board
Jun 25, 2024
Tromsø, Norway, June 25th, 2024—ArcticZymes Technologies (OSE: AZT) Announces Nomination of Dr. Frank Mathias as Chairman of the Board